{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:13:12Z","timestamp":1790719992178,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clinthera.2023.10.020","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T21:57:29Z","timestamp":1700258249000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-7395","authenticated-orcid":false,"given":"Diane","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia T.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.10.020_bib0001","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0002","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014acute lymphocytic leukemia (ALL). https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html. Accessed January 23, 2023."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0003","series-title":"Acute lymphoblastic leukemia version 1. 2022\u2014April 4, 2022","year":"2023"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0004","unstructured":"American Cancer Society. Cancer facts & figures 2023. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2023\/2023-cancer-facts-and-figures.pdf. Accessed January 23, 2023."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0005","unstructured":"Leukemia and Lymphoma Society. ALL subtypes. https:\/\/www.lls.org\/leukemia\/acute-lymphoblastic-leukemia\/diagnosis\/all-subtypes. Accessed January 24, 2023."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0006","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0007","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1038\/srep04227","article-title":"Survival improvement by decade of patients aged 0\u201314 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0008","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0009","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0010","doi-asserted-by":"crossref","first-page":"e85554","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0011","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0012","doi-asserted-by":"crossref","first-page":"414","DOI":"10.6004\/jnccn.2019.0024","article-title":"Acute lymphoblastic leukemia: version 1.2019","volume":"17","author":"Brown","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.beha.2017.08.001","article-title":"Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: current treatment and novel therapies","volume":"30","author":"O'Dwyer","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0014","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0015","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0016","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0017","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/CLML.2011.n.007","article-title":"Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy","volume":"11","author":"Faderl","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0019","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1185\/03007995.2016.1164677","article-title":"Burden of hospitalization in relapsed acute lymphoblastic leukemia","volume":"32","author":"Barlev","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737167.2018.1490645","article-title":"Economic burden with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States","volume":"18","author":"Zhang","year":"2018","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0021","unstructured":"Watson Health. IBM MarketScan Research Databases for life sciences researchers, 2021. https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO. Accessed October 26, 2022."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0022","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Medical Care"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0023","unstructured":"Agency for Healthcare Research and Quality. HCUP chronic condition indicator: healthcare cost and utilization project (HCUP). https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/chronic_icd10\/chronic_icd10.jsp. Accessed October 6, 2021."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0024","first-page":"S1","article-title":"Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases","volume":"25","author":"Wen","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0025","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2023.10.020_sbref0026","series-title":"Medical care in U.S. city average, all urban consumers, not seasonally adjusted (CUUR0000SAM)","year":"2022"},{"key":"10.1016\/j.clinthera.2023.10.020_sbref0027","series-title":"Measuring price change in the CPI: medical care","year":"2022"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0028","series-title":"Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)","article-title":"Real-world treatment patterns, healthcare resource use and hospital provider cost of recently approved treatments for adult relapsed or refractory acute lymphoblastic leukemia (R\/R ALL) in the US: blinatumomab and\/or inotuzumab ozogamicin","author":"Moon","year":"2023"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0029","unstructured":"Russel-Smith A, Shah R, Silverstein A, et\u00a0al. Characteristics, healthcare utilization, and costs associated with inotuzumab ozogamicin, blinatumomab, or other agents for the treatment of relapsed\/refractory acute lymphoblastic leukemia. Poster presented at: European Hematology Association Congress (EHA) 2022; June 9\u201312, 2022; Vienna, Austria."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0030","unstructured":"Blincyto [package insert]. Thousand Oaks, Calif: Amgen Inc; 2023."},{"key":"10.1016\/j.clinthera.2023.10.020_bib0031","unstructured":"Besponsa [package insert]. Philadelphia, Pa: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; 2018."},{"issue":"2","key":"10.1016\/j.clinthera.2023.10.020_bib0032","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/10428194.2019.1672057","article-title":"Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia: real-world resource use data","volume":"61","author":"Lecat","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2023.10.020_bib0034","unstructured":"Kymriah [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:16Z","timestamp":1758963616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823004289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0149291823004289"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}